European Union - English - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.

Canada - English - Health Canada

pharmaceutical partners of canada inc - zinc (zinc sulfate); copper (cupric sulfate); manganese (manganese sulfate); chromium (chromic chloride); selenium (selenious acid); iodide (sodium iodide) - solution - 5mg; 1mg; 0.5mg; 10mcg; 60mcg; 75mcg - zinc (zinc sulfate) 5mg; copper (cupric sulfate) 1mg; manganese (manganese sulfate) 0.5mg; chromium (chromic chloride) 10mcg; selenium (selenious acid) 60mcg; iodide (sodium iodide) 75mcg - replacement preparations

European Union - English - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - umeclidinium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).,

Canada - English - Health Canada

pharmaceutical partners of canada inc - zinc (zinc sulfate); copper (cupric sulfate); manganese (manganese sulfate); chromium (chromic chloride) - solution - 5mg; 1mg; 0.5mg; 10mcg - zinc (zinc sulfate) 5mg; copper (cupric sulfate) 1mg; manganese (manganese sulfate) 0.5mg; chromium (chromic chloride) 10mcg - replacement preparations

Canada - English - Health Canada

pharmaceutical partners of canada inc - zinc (zinc sulfate); copper (cupric sulfate); manganese (manganese sulfate); chromium (chromic chloride) - solution - 1mg; 0.4mg; 0.1mg; 4mcg - zinc (zinc sulfate) 1mg; copper (cupric sulfate) 0.4mg; manganese (manganese sulfate) 0.1mg; chromium (chromic chloride) 4mcg - replacement preparations

European Union - English - EMA (European Medicines Agency)

recordati rare diseases - zinc - hepatolenticular degeneration - other alimentary tract and metabolism products, - treatment of wilson's disease.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

holland & barrett, united kingdom - coated tablet - 25 mg - zinc gluconate 25 mg

United States - English - NLM (National Library of Medicine)

foxland pharmaceuticals, inc. - carbinoxamine maleate (unii: 02o55696wh) (carbinoxamine - unii:982a7m02h5) - carbinoxamine maleate is effective for the symptomatic treatment of: seasonal and perennial allergic rhinitis. vasomotor rhinitis. allergic conjunctivitis due to inhalant allergens and foods. mild, uncomplicated allergic skin manifestations of urticaria and angioedema. dermatographism. as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. amelioration of the severity of allergic reactions to blood or plasma. carbinoxamine maleate is contraindicated in children younger than 2 years of age. carbinoxamine maleate is contraindicated in nursing mothers. carbinoxamine maleate is contraindicated in patients who are hypersensitive to the drug or on monoamine oxidase inhibitor therapy (see drug interactions ).

United States - English - NLM (National Library of Medicine)

foxland pharmaceuticals, inc. - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - for use as adjunctive therapy in the treatment of peptic ulcer. glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. glycopyrrolate tablets are contraindicated in those patients with a hypersensitivity to glycopyrrolate.

United States - English - NLM (National Library of Medicine)

foxland pharmaceuticals, inc. - .alpha.-tocopherol acetate, dl- (unii: wr1wpi7ew8) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), thioctic acid (unii: 73y7p0k73y) (thioctic acid - unii:73y7p0k73y), ubidecarenone (unii: ej27x76m46) (ubidecarenone - unii:ej - this product is contraindicated in patients with a known hypersensitivity to any of the ingredients.